GSK Investigational Site

Saga 849-8501

0 studies enrolling now · 6 studies all time

What they study most

Acute Coronary Syndrome, Arthritis, Rheumatoid, Asthma, Non-alcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease

Studies at this site

• Phase 2b Study of GSK4532990 in Adults With NASH — Running, not enrolling
• An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103) — Completed
• A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype — Completed
• Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs) — Stopped early
• A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma — Completed
• The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial — Completed